EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY-NC-ND 4.0

Euglycemic Diabetic Ketoacidosis Following Ertugliflozin Initiation Precipitated by Norovirus Gastroenteritis

T Michael Farley, Sara Nezirevic

AACE Endocrinology and Diabetes · 2026-09 · 13 (5) · 724-727

DOI: 10.1016/j.aed.2026.05.004 ↗

Kurz gefasst

Fallbericht in der Zeitschrift AACE Endocrinology and Diabetes, 2026-09. Verfasst von T Michael Farley und 1 weiteren Autor:innen. Beteiligte Einrichtung: Associate Professor, South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, South Dakota. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are associated with an increased risk of euglycemic diabetic ketoacidosis (euDKA), a potentially life-threatening complication that can be difficult to recognize due to near-normal blood glucose levels. While infection is a known precipitant of DKA, viral gastroenteritis as a specific trigger for SGLT2 inhibitor-associated euDKA has not been well-characterized. Case Report: A 36-year-old female with type 2 diabetes mellitus presented with severe metabolic acidosis (pH 6.85), anion gap of 23 mEq/L, and blood glucose of 165 mg/dL 1 week after initiating ertugliflozin 15 mg daily in the setting of recent norovirus exposure. The patient was treated per institutional DKA protocol with intravenous fluids, insulin infusion, and dextrose. Ertugliflozin was discontinued and the patient made a full recovery within 48 h.

Discussion

This case illustrates the synergistic mechanism by which norovirus gastroenteritis can precipitate euDKA in patients recently initiated on SGLT2 inhibitors. Viral gastroenteritis causes rapid volume depletion through vomiting and diarrhea, reduced oral carbohydrate intake, and counter-regulatory hormone activation - all of which compound the ketogenic effects of SGLT2 inhibition. Clinicians should counsel patients initiating SGLT2 inhibitors about sick day management and the importance of temporarily discontinuing these agents during acute gastrointestinal illness.

Schlagwörter

Stichwörter der Autor:innen

SGLT2 inhibitorertugliflozineuglycemic diabetic ketoacidosisnorovirusviral gastroenteritis

Autor:innen und Institutionen

  • Associate Professor, South Dakota State University College of Pharmacy and Allied Health Professions, Brookings, South Dakota.
  • Clinical Pharmacist, Transitions of Care, Avera McKennan Hospital & University Health Center, Sioux Falls, South Dakota.
  • Clinical Pharmacist, Northwestern Memorial Hospital, Chicago, Illinois.

Zitieren

APA

Farley, T. M., & Nezirevic, S. (2026). Euglycemic Diabetic Ketoacidosis Following Ertugliflozin Initiation Precipitated by Norovirus Gastroenteritis. AACE Endocrinology and Diabetes, 13(5), 724-727. https://doi.org/10.1016/j.aed.2026.05.004

Vancouver

Farley TM, Nezirevic S. Euglycemic Diabetic Ketoacidosis Following Ertugliflozin Initiation Precipitated by Norovirus Gastroenteritis. AACE Endocrinology and Diabetes. 2026;13(5):724-727. doi:10.1016/j.aed.2026.05.004

BibTeX
@article{Farley2026,
  author = {Farley, T Michael and Nezirevic, Sara},
  title = {Euglycemic Diabetic Ketoacidosis Following Ertugliflozin Initiation Precipitated by Norovirus Gastroenteritis},
  journal = {AACE Endocrinology and Diabetes},
  year = {2026},
  volume = {13},
  number = {5},
  pages = {724--727},
  doi = {10.1016/j.aed.2026.05.004}
}
Kostenlos starten →